Publication

Dual targeting of hepatic fibrosis and atherogenesis by icosabutate, an engineered eicosapentaenoic acid derivative

Liver International 40:2860-2876, 2020

Stokman G, van den Hoek AM, Thorbek DD, Pieterman EJ, Veidal SS, Basta B, Iruarrizaga-Lejarreta M, van der Hoorn JW, Verschuren L, Berbée JFP, Rensen PCN, Skjæret T, Alonso C, Feigh M, Kastelein JJP, Friedman SL, Princen HMG, Fraser DA

Share this page

Resource Library

Related resources

Publication

INT-767 improves histopathological features in a diet-induced ob/ob mouse model of biopsy-confirmed non-alcoholic steatohepatitis

Open

Poster

A3907, a novel inhibitor of bile acid transport in the intestine and the kidney, improves markers of metabolic and hepatic pathology and reduces NAFLD activity score and fibrosis stage in a diet-induced and biopsy-confirmed mouse model of nonalcoholic steatohepatitis

Open

Publication

Animal models of type 2 diabetes, obesity and nonalcoholic steatohepatitis – clinical translatability and applicability in preclinical drug development

Open

Dual targeting of hepatic fibrosis and atherogenesis by icosabutate, an engineered eicosapentaenoic acid derivative

Related resources

For further information

Contact us

Gubra